BioXcel Therapeutics, Inc. (BTAI)
Confidential investigation: officers & directors’ potential breach of fiduciary duties to investors.
Investigation
06/09/2021
Initial Lawsuit
06/09/2021
Lawsuit Progression
08/31/2021
Investigation regarding statements made by RLX in connection with its initial public offering (IPO), e-cigarettes regulations in China and their impact on the company’s business.
03/22/2021
New outlets report on the Ministry of Industry and Information Technology (MIIT) and China’s State Tobacco Monopoly Administration, posting online the draft regulations “to bring the rules governing the sale of e-cigarettes and other new tobacco products in line with those for ordinary cigarettes.“
Stock Impact
Close | Previous close | Price variation | Percentage variation |
---|---|---|---|
$10.15 | $19.46 | $-9.31 | -47.84% |
Plaintiff brings this securities class action on behalf of persons who purchased, or otherwise acquired, RLX American Depository Shares pursuant or traceable to the F-1 registration statement (including all amendments made thereto) and related prospectus on Form 424B4 issued in connection with RLX’s January 2021 initial public stock offering.
According to the complaint, defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the company’s business, operations, and prospects. Specifically, defendants allegedly failed to disclose to investors that:
China was working on a national standard for e-cigarettes that would bring them into line with regular cigarette regulations. Because the Registration Statement did not disclose the then-known existential threat that China’s ongoing push to regulate the industry posed, and the impact such regulation was already having, and certain to continue to have, on the Company’s business and prospects, Plaintiff and other ADS purchasers had no opportunity to adequately assess the value of the shares offered in connection with the IPO.
08/31/2021
The court issued an order appointing the lead plaintiff and lead counsel.
08/04/2021
Plaintiff brings this securities class action on behalf of persons: (1) who purchased, or otherwise acquired, RLX American Depositary Shares (ADS) pursuant or traceable to the F-1 registration statement (including all amendments made thereto) and related prospectus on Form 424B4 issued in connection with RLX’s January 2021 initial public stock offering (IPO); and (2) who purchased, or otherwise acquired, RLX ADS between January 22, 2021 and June 2, 2021, inclusive.
Additional amended complaints have been filed, please refer to the last filed amended complaint for up-to-date information.
11/09/2021
This is a federal securities class action on behalf of all persons or entities who purchased or otherwise acquired RLX American Depositary Shares (ADS) pursuant or traceable to the F-1 registration statement (including all amendments made thereto) and related prospectus on Form 424B4 issued in connection with RLX’s January 2021 initial public stock offering (IPO) and who were damaged thereby.
Operative complaint
12/23/2021
A motion to dismiss was filed with the court.
Confidential investigation: officers & directors’ potential breach of fiduciary duties to investors.
Whether directors and officers of Payoneer Global Inc. (PAYO) breached their fiduciary duties to the company and its shareholders.
Whether directors and officers of Kewaunee Scientific Corporation (KEQU) breached their fiduciary duties to the company and its shareholders.
Whether directors and officers of Inari Medical, Inc. (NARI) breached their fiduciary duties to the company and its shareholders.
Whether directors and officers of LegalZoom.com, Inc. (LZ) breached their fiduciary duties to the company and its shareholders.
Whether directors and officers of Amicus Therapeutics, Inc. (FOLD) breached their fiduciary duties to the company and its shareholders.